Fabrication, appraisal, and transdermal permeation of sildenafil citrate-loaded nanostructured lipid carriers versus solid lipid nanoparticles by Elnaggar, Yosra SR et al.
© 2011 Elnaggar et al, publisher and licensee Dove Medical Press Ltd.   This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
International Journal of Nanomedicine 2011:6 3195–3205
International Journal of Nanomedicine Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
3195
OrIgINAL rEsEArch
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/IJN.S25825
Fabrication, appraisal, and transdermal permeation 
of sildenafil citrate-loaded nanostructured lipid 
carriers versus solid lipid nanoparticles
Yosra sr Elnaggar1
Magda A El-Massik2
Ossama Y Abdallah1
1Department of Pharmaceutics, 
Faculty of Pharmacy, Alexandria 
University, 2Department of 
Pharmaceutics, Faculty of Pharmacy 
and Drug Manufacturing, Pharos 
University, Alexandria, Egypt
correspondence: Yosra sr Elnaggar 
Department of Pharmaceutics,  
Faculty of Pharmacy, Alexandria 
University, 1 Khartoum square,  
Azarita, Messalla Post Office,  
PO Box 21521, Alexandria, Egypt 
Tel +203 487 0359 
Fax +203 487 3273 
Email yosra_pharm@yahoo.com
Abstract: Although sildenafil citrate (SC) is used extensively for erectile dysfunction, oral 
delivery of SC encounters many obstacles. Furthermore, the physicochemical characteristics 
of this amphoteric drug are challenging for delivery system formulation and transdermal 
  permeation. This article concerns the assessment of the potential of nanomedicine for improving 
SC delivery and transdermal permeation. SC-loaded nanostructured lipid carriers (NLCs) and 
solid lipid nanoparticles (SLNs) were fabricated using a modified high-shear homogenization 
technique. Nanoparticle optimization steps included particle size analysis, entrapment efficiency 
(EE) determination, freeze-drying and reconstitution, differential scanning calorimetry, in vitro 
release, stability study and high-performance liquid chromatography analysis. Transdermal 
permeation of the nanocarriers compared with SC suspension across human skin was assessed 
using a modified Franz diffusion cell assembly. Results revealed that SLNs and NLCs could be 
optimized in the nanometric range (180 and 100 nm, respectively) with excellent EE (96.7% and 
97.5%, respectively). Nanoparticles have significantly enhanced in vitro release and transdermal 
permeation of SC compared with its suspensions. Furthermore, transdermal permeation of SC 
exhibited higher initial release from both SLN and NLC formulations followed by controlled 
release, with promising implications for faster onset and longer drug duration. Nanomedicines 
prepared exhibited excellent physical stability for the study period. Solid nanoparticles   optimized 
in this study successfully improved SC characteristics, paving the way for an efficient topical 
Viagra® product.
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Introduction
Erectile dysfunction has been defined as the inability to attain and/or maintain a penile 
erection sufficient for satisfactory sexual performance. Although erectile dysfunction 
represents a major clinical problem, medical therapy for this condition was invasive 
or ineffective before the introduction of sildenafil citrate (SC).1 SC is the first oral 
treatment to have had significant success in the treatment of erectile dysfunction. 
It acts via selective inhibition of the enzyme phosphodiesterase type 5. The physiologic 
mechanism of penile erection involves release of nitric oxide in the corpora cavernosa 
during sexual stimulation. This release activates the enzyme guanylate cyclase, relaxing 
the smooth muscle of the corpus cavernosum and allowing greater blood flow, thus 
leading to an erection.2,3 SC is an amphoteric drug with a pH-dependent solubility. 
The drug possesses a basic functional group (NH-piperazine), characterized by a pK 
value of 8.7, in addition to a weak acidic moiety (HN-amide), as shown in Figure 1. International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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SC is marketed as Viagra® oral tablets, with doses of 25, 50, 
and 100 mg taken not more than once a day.4
Unfortunately, oral administration of SC encounters 
numerous obstacles. The drug is vulnerable to considerable 
intestinal and hepatic first-pass metabolism (approximately 
71% of oral dose).5 The drug is metabolized in the liver by 
the enzyme cytochrome P3A4, with an oral bioavailability of 
40%. Furthermore, numerous side effects such as blood pres-
sure reduction, headaches, flushing, and nasal congestion are 
concomitant with oral   administration. Patients with moderate 
to severe cardiovascular disease or those undergoing nitrate 
therapy are at increased risk for potentially serious adverse 
cardiovascular side effects with SC therapy. In addition, 
relatively delayed onset (30–45 minutes) and short duration 
of action have been demonstrated for SC, with a half-life 
of 4 hours. In the meantime, repeated doses are required to 
sustain drug plasma levels.6,7
Transdermal delivery of SC through a local tissue area 
could be considered as an alternative to the oral route, in 
order to avoid these adverse side effects, to shorten onset 
time, and to sustain the effect for longer periods.8 In this 
context, nanosized colloidal carriers have been the subject of 
widespread interest in the field of transdermal drug delivery.8 
Among these, solid lipid nanoparticles (SLNs) and nanostruc-
tured lipid carriers (NLCs) are attracting major attention as 
novel colloidal nanocarriers for topical use. Compared with 
liposomes and polymeric nanoparticles, SLNs exhibit the 
peculiarity of higher stability, capability of large-scale appli-
cation, and avoidance of organic solvent incorporation.9,10 
Compared with other topical vehicles such as creams, tinc-
tures, and emulsions, combined advantages of SLNs include 
controlled release, negligible skin irritation, and protection of 
active compounds.7 Enhanced topical permeation via SLNs 
and NLCs is well recognized in the literature.11,12 Drugs 
that have exhibited improved transdermal penetration when 
incorporated into SLNs include flurbiprofen,13 ascorbyl 
palmitate,14 and ketorolac.15 On the other hand, NLCs are 
the second generation of SLNs incorporating a solid matrix 
that entraps variable liquid lipid nanocompartments. NLCs 
have been shown to possess improved drug loading, adjusted 
drug release, and minimum drug expulsion during storage.16 
NLCs remain in their solid state through controlling the   liquid 
lipid content added to the formulation; therefore, controlled 
drug release properties can be achieved with NLCs.17 
NLCs have also proved effective in the field of transdermal 
drug permeation.18
Nevertheless, a general challenge facing transdermal 
delivery of drugs is low skin permeation; reasons for this 
include the physicochemical properties of the compound, 
low partition ability, and formidable barrier properties of 
the stratum corneum. The majority of drugs do not appear to 
penetrate the skin at a sufficiently high rate to show therapeutic 
effectiveness. The feasibility of the transdermal route is thus 
limited to powerful actives presenting features such as 
appropriate low molecular weight and high lipophilicity.8 
Further challenges in delivery-system formulation and 
transdermal permeation of SC are the amphoteric nature and 
pH-dependent characteristics of the compound. The drug 
possesses poor solubility in both aqueous and oil phases.4 
Furthermore, in different pH environments, the drug will 
have different levels of ionization following the influence 
of the partition coefficient, as well as its permeation ability 
via the skin. Therefore, modification of the permeation 
parameters of SC has been reported as a major task in the 
development of an optimal drug for topical delivery formula; 
this includes improvement of onset time, maintenance of 
plasma level, and enhancement of skin permeation with 
subsequent lowering in dose and adverse effects.2,4 Yonessi 
and Saeedi3 investigated the effect of topical gel containing 
SC (1% SC in different cosolvents) compared with SC oral 
tablets on erectile dysfunction. They reported a significantly 
shorter onset of action and lower side effects for transdermal 
SC delivery. However, only 12.5% of patients had complete 
erection with transdermal SC delivery, compared with 
70% of patients receiving oral therapy. Yonessi and Saeedi3 
suggested that several percutaneous absorption enhancers 
could enhance transdermal SC delivery; this appears to be 
a promising approach for treatment of erectile dysfunction. 
However, no published trials on SC delivery systems and 
transdermal application have emerged so far.
Realizing the obstacles of SC oral delivery, the 
development of SC drug delivery systems for improving 
drug characteristics and therapy becomes a substantial 
  undertaking. The aim of the study outlined in this article was 
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to improve SC delivery characteristics using nanocarriers. In 
a previous study, the present authors investigated self-nanoe-
mulsifying drug delivery systems and nanoemulsions for this 
purpose.19 In the current study, formulation and full in vitro 
appraisal of SC-loaded SLNs and NLCs were performed. 
The developed nanoparticles were designed in the previous 
study to fit both oral and topical application, whereas in the 
current investigation transdermal permeation of the prepared 
nanocarriers via human skin were assessed and compared 
with different drug suspensions. Furthermore, the physical 
shelf stability of both nanocarriers was assessed.
Materials and methods
Materials
SC was obtained from Sun Pharmaceutical Industries Ltd 
(Mumbai, India). Cetyl palmitate (CP) was obtained from 
Goldschmidt (Essen, Germany). Gattefossé (Lyon, France) 
kindly donated glycerol monolinoleate (Maisine™ 35-1 [M]). 
Polyoxyl 40 hydrogenated castor oil (Cremophor® RH 40 [CR]) 
was obtained from BASF (Ludwigshafen, Germany). Span™ 
85 (hydrophilic-lipophilic balance (HLB) = 1.8) was obtained 
from Sigma-Aldrich (St Louis, MO). Propylene glycol and 
Tween 80 were obtained from Al-Nasr Pharmaceutical 
Chemicals Co (Cairo, Egypt). All other chemicals used were 
of analytical grade.
High-performance liquid chromatography
For this study, the authors utilized a previously validated 
high-performance  liquid  chromatography  (HPLC) 
methodology20 with minor modifications, as outlined in the 
authors’ previous work.19 The HPLC instrument (Series 
200; PerkinElmer Inc, Waltham, MA) was equipped with 
a reversed-phase C18 column (25 cm × 4.6 mm; particle 
size = 5 µm). The isocratic mobile phase, 20 mmol/L 
monopotassium phosphate (pH 4.7):acetonitrile (25:75), 
was run at a flow rate of 1.0 mL per minute at room 
temperature and the column effluent was monitored by 
an ultraviolet detector set at 293 nm. A 20 µL volume of 
each sample was automatically injected into the analytical 
column. Samples were injected concurrently within the 
standard solutions injections. The system was also equipped 
with a 600 Series Link Interface operated by TotalChrom 
chromatography data system software (v 6.2; PerkinElmer 
Inc, Waltham, MA). The calibration curve of peak area 
against SC concentration was Y = 862402.4 X −42324.3, 
under SC concentration of 0.5–9 mg%. Retention time 
was 4.3 plus or minus 0.3 minutes (R2 = 0.9956; limit of 
quantification = 0.7 µg/mL; accuracy = 96.6%).
Preparation of sLNs and NLcs
As a consensus in the literature, high-pressure homogeni-
zation (HPH) is considered the optimum method for SLN 
formation. This is ascribed to exploitation of low surfactant 
content and avoidance of organic solvent incorporation.10 
Nevertheless, HPH results in high particle surface energy 
and lower stability.17 In the current study, SLNs and NLCs 
were prepared using a modified high-shear homogeniza-
tion method, in an attempt to combine the privileges of 
HPH while circumventing high-pressure implications. Two 
methods of drug loading, during and after carrier formation, 
were compared. In the first method, drug was dispersed in 
the surfactant/cosurfactant mixture (CR, Span 85, propylene 
glycol) using sonication (Julabo sonicator, USR-3; Julabo 
Labortechnik GmbH, Seelbach, Germany). Dispersion 
was aided by heating in the shaking water bath at 70°C for 
5 minutes. Afterwards, the wax (CP) was added to the blend 
and melting was pursued for 20 minutes at 70°C. Water was 
heated separately to the same temperature and was then added 
to the component blend under high-shear homogenization at 
3000 rpm, at 70°C for 5 minutes (T 25 digital Ultra-Turrax®; 
IKA, Staufen, Germany). The hot emulsion formed was 
poured into a fourfold volume of cold, distilled water under 
high-shear homogenization at 7000 rpm. Homogeniza-
tion was pursued in a cold-water bath for 30 minutes. The 
nanoparticle dispersion formed was then filtered through a 
0.8 µm membrane filter (diameter 25 mm; Micro Filtration 
Systems, Dublin, CA).
In the second method, solid lipid and surfactant blend 
were mixed and heated to 70°C for 20 minutes. Distilled 
water heated to the same temperature was then added 
under high-shear homogenization at 3000 rpm, at 70°C 
for 5 minutes. The hot emulsion formed was poured into 
a fourfold volume of cold, distilled water under high-shear 
homogenization at 7000 rpm. The placebo nanoparticles 
formed were then passed through a 0.8 µm membrane 
filter. After lipid nanoparticles were formed, drug was 
added quantitatively to SLN dispersion and sonicated for 
15 minutes. As for NLCs, the liquid lipid (M) was mixed 
with the surfactant mixture. Dispersion was aided by 
heating in the shaking water bath at 70°C for 5 minutes. 
The same steps were then repeated for both methods 
(before and after carrier formation). For both SLNs and 
NLCs, two external phases (carbonate buffer [pH 10.3] and 
distilled water) were utilized and compared for their effect 
on nanoparticle characteristics. Composition of different 
SLN and NLC formulations is shown in Tables 1 and 2, 
respectively.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Particle size analysis
Average particle size was measured using a laser diffraction 
particle size analyzer (Cilas 1064; Cilas, Orléans, France). 
SLN and NLC dispersions were diluted with distilled water to 
concentrations of 0.25% and 7%, respectively. Samples were 
ultrasonicated for 3 minutes before measurement. Results 
were represented as mean particle size (duplicate) plus or 
minus standard deviation (SD).
Entrapment efficiency determination
The entrapment efficiency (EE) of the prepared SLNs and 
NLCs was assessed using Vivaspin ultracentrifuge tubes 
(Vivaspin® 6 Centrifugal Concentrator, molecular weight 
cutoff [MWCO] 100,000; Vivaproducts, Inc, Littleton, MA). 
Nanoparticle dispersion (3 mL) was added to the centrifuge 
tube and centrifugation was carried out for 15 minutes at 
4000 rpm. The filtrate was diluted (1:3) with distilled water, 
and EE was determined as a percentage through the follow-
ing equation:
  EE% =
Mi Mf
Mi
−× 100
  (1)
In this equation, Mi is the initial weight of SC and Mf is the 
weight of the free (unentrapped) drug detected in the filtrate. 
Samples were measured using the previously detailed HPLC 
method. Results were represented as the mean percentage 
(duplicate) plus or minus SD.
Freeze-drying and reconstitution
Nanoparticle dispersion (15 mL) was placed in 50 mL 
vials. Mannitol was added to the nanoparticle dispersion as 
a   cryoprotectant in a final concentration of 4% (w/v). The 
vials were frozen at −80°C for 4 hours and were then placed 
in a lyophilizer (Cryodos-50; Telstar, SA, Terrassa, Spain) 
with a condenser temperature of −70°C. Lyophilization was 
  performed at a pressure of 40 mbar and a shelf temperature 
of −40°C for 1 day, followed by a secondary drying at 25°C 
for another day. Lyophilized samples were kept at −80°C until 
used. Reconstitution was carried out by manual redispersion 
of lyophilized samples in 15 mL of distilled water. Samples 
were then suitably diluted with distilled water (1:100) and 
particle size was measured using the laser diffraction   particle 
size analyzer. Sonication was carried out for 3 minutes before 
measurement.
Differential scanning calorimetry
Differential scanning calorimetry (DSC) was employed 
to study thermal behavior and detect polymorphism of 
SLNs compared with NLCs. DSC thermograms of selected 
samples were obtained using a differential scanning 
  calorimeter (PerkinElmer, Rodgau, Germany). The selected 
samples were:
•	 CP heated to the same procedure temperature (70°C) as 
SLN and cooled suddenly in the same way (cold-water 
bath)
•	 physical mixture of CP and M (CP:M PH MIX) in 
  formulation ratio (0.7:0.3), prepared in the same way as 
the CP sample
•	 physical mixture of CP, M, and CR (CP:M:CR PH MIX) 
in formulation ratio (0.7:0.3:1.3), prepared in the same 
way as the CP sample
•	 freeze-dried SLN (zero cryoprotectant)
•	 freeze-dried NLC (zero cryoprotectant)
•	 SC powder (as received).
Samples (10 mg) were weighed, hermetically sealed 
in an aluminum pan, and heated at a constant temperature 
increase rate of 5°C per minute over a temperature range 
of 20°C–200°C. The melting point, enthalpies, and onset 
  temperature of the transition observed were reported.
Table 1 Composition of sildenafil citrate (SC)-loaded solid lipid 
nanoparticle formulations (% w/v)a
Formula SC CP CR Span™ 85 Carbonate  
buffer
Water
Xa 0.05 2 4 – – 13
Xb 0.05 2 3 1 – 13
X1 0.05 2 2.6 1.4 – 13
X2 0.075 2 2.6 1.4 – 13
X3 0.1 2 2.6 1.4 – 13
X4 0.075 2 2.6 1.4 13 –
X5b 0.075 2 2.6 1.4 13 –
X6b 0.1 2 2.6 1.4 13 –
Notes: aAll formulae contain 1% propylene glycol as cosurfactant; bdrug added after 
carrier formation.
Abbreviations: CP, cetyl palmitate; CR, Cremophor® rh 40.
Table  2  Composition  of  sildenafil  citrate  (SC)-loaded  nano-
structured lipid carrier formulations (% w/v)a
Formula SC CP M CR Span™ 85 Carbonate  
buffer
Water
N1 0.05 1.4 0.6 2.6 1.4 – 13
N2 0.075 1.4 0.6 2.6 1.4 – 13
N3 0.1 1.4 0.6 2.6 1.4 – 13
N4 0.075 1.4 0.6 2.6 1.4 13 –
N5b 0.075 1.4 0.6 2.6 1.4 13 –
N6b 0.1 1.4 0.6 2.6 1.4 13 –
Notes: aAll formulae contain 1% propylene glycol as cosurfactant; bdrug added after 
carrier formation.
Abbreviations: CP, cetyl palmitate; CR, Cremophor® RH 40; M, Maisine™ 35-1.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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In vitro drug release
The in vitro drug release was assessed using the dialysis 
bag method.21 Drug release from optimum SLN formulation 
was compared with optimum NLC formulation, placebo 
nanoparticle dispersions, and drug suspension. SC was 
suspended in carbonate buffer (pH 10.3) (nanoparticle external 
phase) yielding suspension with the same drug strength of 
nanoparticles (0.1 g% w/v). Nanoparticle dispersions and 
drug suspension (7.5 mL) were added to the dialysis bag 
(Visking® 36/32, 27 mm, MWCO 12,000–14,000; Serva, 
Heidelberg, Germany). The bag was fixed to a 100 mL glass-
stoppered container holding 50 mL of citrate buffer (pH 5). 
The experiment was carried out in a thermostated shaking 
water bath set at 37°C and 100 rpm. A placebo nanoparticle 
experiment was carried out concurrently. All samples were 
measured using HPLC analysis. All experiments were 
performed in triplicate. Results are presented as mean 
percentage of release plus or minus SD.
Transdermal permeation study
skin collection and preparation
Intact, full-thickness human skin was obtained from arm 
plastic surgery. The subcutaneous fatty tissue was removed 
from the skin using a scalpel and surgical scissors. The skin 
surface was cleaned with Ringer’s solution and allowed to 
dry. Skin was completely covered by saline-immersed   tissue, 
packed in aluminum foil, and stored in a polyethylene bag 
at −20°C. Human skin has been reported to be stable for 
3–6 months under these conditions.22 All investigations were 
conducted in full compliance with the ethical principles of 
Mustafa El-Naggar Hospital (Semoha, Alexandria, Egypt).
sample preparation and Franz diffusion cell assembly
Transdermal permeation of SC from the two nanocarriers 
developed was compared with that from drug suspensions in 
two nanocarrier external phases (carbonate buffer [pH 10.3] 
and water) using the same sample volume (0.75 mL) and 
final concentration (0.1%). The applied sample volume 
had considered unified amount of drug in all formulations 
(0.75 mg) to circumvent the concentration gradient effect on 
the rate of drug release.
Transdermal permeation of SC from the elaborated nano-
medicines was assessed using a modified Franz diffusion cell 
assembly23 under nonocclusive conditions. The skin samples 
were mounted on modified Franz diffusion cells with a sur-
face area of 3.14 cm2 and a receptor volume of 8.5 mL. The 
skin was fixed so that the dermal side of the skin was exposed 
to the receptor fluid and the hypodermis remained in contact 
with the donor compartment. The receptor fluid consisted of 
citrate buffer solution (pH 5). After an equilibration time of 
15 minutes at 32°C, formulations were applied in the donor 
compartment through direct contact to the skin. Diffusion 
cells were placed in a thermostatically controlled shaking 
water bath (type 3047; Köttermann, Hänigsen, Germany). 
Diffusion cells were shaken at 100 rpm, while the temperature 
was maintained at 32°C, simulating skin surface temperature. 
Sampling was performed at 0.5, 1.5, 5, and 24 hours. At each 
point, a 3 mL sample was withdrawn and replaced with fresh 
buffer. All experiments were carried out in triplicate. The 
HPLC method was used to measure the concentration of SC 
permeated in skin effluent samples.
stability study
Stability study of selected SLN and NLC dispersions was 
carried out for 6 months. The nanodispersions were packed 
in well-sealed amber glass bottles at 4°C. Samples were 
taken each month and were analyzed for EE and particle 
size. In addition, nanodispersions were visually inspected 
for any physical instability (separation, aggregations, and 
so forth).
statistical analysis
Statistical analysis of the results was carried out using 
Student’s t-test (P , 0.05).
Results and discussion
CP is a lipid wax used in SLN preparation24 and is also well 
recognized in topical application of SLNs.18 SLNs prepared 
with CP have successfully enhanced the oral bioavailability 
of nitrendipine via lymphatic targeting.25 Furthermore, CP-
based SLNs exhibited high physical stability compared with 
mono- and triglycerides.26 Preliminary studies investigated 
drug solubility in different system components. Different 
surfactants, cosurfactants, oily phases, and buffer systems 
were investigated.19 The ingredient that exhibited higher 
drug solubilization was picked up for nanoparticle formation. 
CR, propylene glycol, and M were chosen as the optimum 
surfactant, cosurfactant, and oily phase, respectively.
The influence of numerous factors on particle size and 
EE was investigated. Eight SLN formulations and six NLC 
formulations were prepared to study the effects of these 
factors on formula characteristics, as shown in Tables 1 and 2, 
respectively. Characterization of SLNs and NLCs was based 
on particle size analysis and EE assessment, as shown in 
Tables 3 and 4, respectively. The factors investigated included 
(1) ratio of CR to Span 85; (2) drug dosage influence; (3) International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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pH of the nanoparticle external phase; and (4) method of 
drug loading.
ratio of cr to span 85
An initial attempt of lipid nanoparticle preparation involved 
studying different ratios of CR (as oil-in-water emulsi-
fier; HLB = 15) to Span 85 (as water-in-oil emulsifier; 
HLB = 1.8). Three ratios were compared: 100:0 (Xa), 
75:25 (Xb), and 65:35 (X1). As Table 1 shows, the use of 
oil-in-water surfactant only (Xa) resulted in microparticles 
rather than nanoparticles. The addition of a water-in-oil 
emulsifier (Xb) resulted in a significant decrease in particle 
size (540 nm). Higher percentage of Span 85 (X1) resulted 
in further significant decrease in particle size (360 nm). This 
could be explained regarding the required HLB value for CP 
(HLB = 10). Realizing that the average HLB of CR is 15, 
large particle size of Xa (1.13 µm) could be justified. The 
HLB of the surfactant blend in Xb is 11.7 (Equation 2), while 
the HLB of the X1 surfactant blend is 10.4. The closeness of 
the X1 HLB to the required HLB of the lipid could explain 
its smaller particle size compared with Xb.
HLB (SAA blend) =   HLB (CR) ×	% (CR) + HLB  
(Span 85) ×	% (Span 85)  (2)
(SAA = surface active agent.) The elaborated surfactant 
blend ratio (65:35) was used for preparation and further 
optimization of SLNs and NLCs. The ratio of oil to solid 
lipid was fixed at 30:70 in all NLC formulations. This is 
the most common ratio in oil-loaded SLN formulations. No 
attempts to increase M ratio were adopted to avoid significant 
reduction in CP melting point, taking into consideration its 
original low melting point (43°C–53°C).
Drug dosage influence
In order to study the effect of increasing drug dose on for-
mula characteristics, three SLN formulations (X1, X2, X3) 
(see Table 1) and three NLC formulations (N1, N2, N3) 
(see Table 2) were prepared. The formulae comprised three 
drug amounts (50, 75, and 100 mg% w/v) respectively. As 
Table 3 shows, the EE value of SLN formulae decreased 
significantly as the drug load increased. Increasing drug dose 
from 50 to 75 mg resulted in an increase in the entrapped 
weight in both SLNs and NLC. Nevertheless, by increasing 
the dose from 75 to 100 mg, the entrapped drug amount in 
SLN formulae was fixed to almost the same value (46.5 mg). 
This value is consistent with the sum drug solubility in all 
nanoparticle ingredients with their applied ratios. As for 
NLC formulations (Table 4), a slight increase in SC mg 
entrapped was noticed in N2 (47.62 mg) or N3 (48.80 mg) 
compared with their analogues X2 and X3, respectively. The 
drug amount exceeding solubility in ingredients is supposed 
to partition into the external phase (water), in which it is 
relatively more soluble than in solid lipid. The slight improve-
ment could be ascribed to incorporation of M into the lipid 
matrix. As there was no significant improvement realized in 
EE through increasing the drug dose from 75 to 100 mg, the 
following factor effect was studied based on a SC dose of   
75 mg (w/v).
ph of the nanoparticle external phase
In an attempt to increase the EE of drug-loaded SLN and 
NLC formulae, the use of a nanoparticle external phase 
with minimum drug affinity was investigated. The lowest 
drug affinity to the nanoparticle aqueous phase is supposed 
to permit higher drug accumulation inside lipid nano-
particles and on the shell. Therefore, drug solubility in 
different pH buffer systems was assessed. The buffers used 
were citrate buffer (pH 5), phosphate buffer (pH 7.4), and 
Table 3 Characterization of sildenafil citrate (SC)-loaded solid 
lipid nanoparticles
Formula Mean particle  
size (μm)
SC entrapped  
(mg)
EE (%)
Xa 1.13 ± 0.03 38.60 ± 1.13 96.50 ± 3.88
Xb 0.54 ± 0.01 35.15 ± 0.64 87.75 ± 1.59
X1 0.36 ± 0.02 36.10 ± 1.55 90.25 ± 3.88
X2 0.33 ± 0.07 46.55 ± 0.28 77.58 ± 0.47
X3 0.35 ± 0.14 46.76 ± 0.06 58.45 ± 0.07
X4 0.34 ± 0.40 50.79 ± 0.76 84.64 ± 1.26
X5 0.21 ± 0.60 73.02 ± 0.42 97.36 ± 0.56
X6 0.18 ± 0.15 96.65 ± 0.49 96.65 ± 0.49
Note: Data presented as mean ± standard deviation.
Abbreviation: EE, entrapment efficiency.
Table 4 Characterization of sildenafil citrate (SC)-loaded nano-
structured lipid carriers
Formula Mean particle  
size (μm)
SC entrapped  
(mg)
EE (%)
N1 0.34 ± 0.22 37.39 ± 1.14 93.47 ± 2.83
N2 0.30 ± 0.14 47.62 ± 0.12 79.35 ± 0.20
N3 0.32 ± 0.13 48.80 ± 0.22 68.95 ± 3.37
N4 0.28 ± 0.05 58.35 ± 1.20 95.83 ± 2.00
N5 0.13 ± 0.03 73.80 ± 0.14 98.40 ± 1.13
N6 0.10 ± 0.21 97.50 ± 0.52 97.5 ± 0.52
Note: Data presented as mean ± standard deviation.
Abbreviation: EE, entrapment efficiency.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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carbonate buffer (pH 10.3). It was found that drug solubility 
decreased significantly as the pH increased. Drug solubil-
ity was lowest in carbonate buffer (0.05 mg/mL), followed 
by phosphate buffer (0.09 mg/mL), and was highest with 
citrate buffer (2.25 mg/mL). This could be explained by 
the basic functional group of the drug (NH-piperazine, pKa 
8.7). The reverse relationship between sildenafil solubility 
and solvent pH is reported elsewhere.4 The buffer system 
with the lowest drug solubilizing capacity (carbonate buffer, 
pH 10.3) was selected for the next preparations of SLN (X4) 
and NLC (N4). The prepared formulations were compared 
with their analogues prepared with water as external phase 
(X2 and N2, respectively). For SLNs (see Table 3), elevation 
of external phase pH resulted in an increase in the amount 
of drug entrapped: X4 had 50.79 mg; X2 had 46.5 mg. A 
more pronounced and significant increase was noticed in 
NLC formulation N4 (58.35 mg), prepared with carbonate 
buffer, compared with N2 (47.62 mg) (see Table 4). The 
enhanced improvement in EE of NLCs compared with 
SLNs could be explained by the fact that the solubility of 
active ingredients in oils is generally higher than in solid 
lipids. For this reason, the higher loading capacity could be 
achieved through the development of NLCs.16,24 It is worth 
noting that the pH of 10.3 was selected based on the literature 
investigating the topical and sublingual absorption of SC. 
Lia and Chang2 have reported that the transport amount of 
SC had the highest permeation rate in nude mouse skin, at 
pH 8–11. On the other hand, Wang et al7 have contended that 
a pH of 10.3 is optimum for sublingual permeation of SC. 
Therefore, the pH of 10.3 was selected as a compromise, to 
prepare nanoparticles that could be useful for both routes of 
administration. The alkaline buffer (pH 10.3) was selected 
as carbonate/bicarbonate constituents, while borax buffer 
was avoided. This was ascribed to the safety, regarding oral 
route, of the former buffer compared with the latter. Carbon-
ate buffer was reported to be safe for both oral and topical 
application. The acute oral median lethal dose (LD50) for 
carbonate buffer in rats is 2.8 g/kg, while the dermal LD50 in 
rats is .3 g/kg. In addition, sodium carbonate has no or only 
a low skin irritation potential.27
Method of drug loading
The previous optimization steps have indicated optimum 
components, optimum formulation ratios, and optimum 
aqueous phase pH. For this step, SLNs (X4) and NLCs 
(N4) with high EE (84.64% and 95.83%, respectively) and 
reasonable particle size (340 and 280 nm, respectively) 
could be obtained. Nevertheless, although it combines 
many advantages, the high-shear homogenization method 
utilized in the study suffers from drug loss in the filtration 
step. This loss was confined to 20% plus or minus 1% of the 
labeled drug amount. In an attempt to decrease such loss, a 
different method of drug addition was assessed. The drug was 
alternatively loaded to nanoparticles after carrier formation 
and the filtration step, as explained earlier in the section on 
preparation of SLNs and NLCs. The SLN formulation X5 
(Table 1) and the NLC formulation N5 (Table 2) were 
prepared exactly as X4 and N4, except that drug was added 
after the filtration step. The amount of SC incorporated was 
significantly increased when drug was added after carrier 
formation, for both SLNs and NLCs (Tables 3 and 4, 
respectively). Regarding SLNs, there was a significant increase 
in drug entrapped in X5 (73 mg) compared with X4 
(50 mg). A significant increase was also noticed in the NLC 
formulation N5 (73.6 mg) compared with N4 (58.35 mg). To 
test the improved EE observed with the second method of 
addition, a higher SC dose (100 mg) was used in both SLNs 
(X6) and NLCs (N6). It was found that the amount of drug 
entrapped was also significantly enhanced in both cases. 
SLNs with 96.65 mg of SC entrapped and with a particle 
size of 180 nm could be prepared. Furthermore, the NLC 
formulation N6 with 97.5 mg of SC entrapped and a particle 
size of 100 nm could be prepared. For formulae X5, X6, N5, 
and N6 prepared via drug addition after carrier formation, 
a smaller globular size than others may be attributed to the 
additional sonication step.
Dsc
In order to circumvent interfering peak of water, nanopar-
ticle dispersions were subjected to DSC in the lyophilized 
form.16 Selected samples were thermally analyzed in an 
attempt to compare thermal characteristics of SLNs and 
NLCs. Results are demonstrated in Figure 2 and Table 5. 
CP revealed two peaks, a very minor peak at 32.4°C and a 
major peak at 47.12°C. Such a behavior of the solid lipid 
reflects two distinct polymorphic forms. From the literature 
reviews, the form with the lower melting point is attributed 
to α-polymorphic form, whereas the latter is attributed to 
the most stable β-polymorphic form. The melting point of 
CP in both SLNs (43.6°C) and NLCs (42.5°C) is lower than 
that of bulk material (45.6°C). While the melting point in 
NLCs was lower than SLNs by only one degree, the minor 
reduction in melting point reflects minor disturbance in the 
structure and crystallinity of CP through the addition of the International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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applied ratio of oil. This was supported by a comparison of the 
  melting point of CP (45.6°C) with that of the lipid:oil physical 
  mixture (44.5°C). These data explained and   supported results 
of EE that demonstrated a minor difference in drug entrapped 
between SLNs and NLCs. This effect could be ascribed to the 
highly impacted crystalline structure of CP reported.26 It is 
worth noting that SC peak (190°C) did not appear in either 
SLN or NLC thermograms, owing to its very low percentage 
in the mixture (0.83%).
In vitro release study
In the process of biological permeation, the drug should 
first release from the vehicles, and then it can be partitioned 
into or absorbed by the skin or gastrointestinal tract.11 
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Figure 2 Differential scanning calorimetry thermograms of cetyl palmitate (CP); CP:Maisine™ 35-1 physical mixture (CP:M PH MIX) (0.7:0.3); CP:M:Cremophor® rh 40 
physical mixture (CP:M:CR PH MIX) (0.7:0.3:1.3); nanostructured lipid carriers (NLCs), solid lipid nanoparticles (SLNs), and sildenafil citrate (SC).International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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As a consequence, assessment of in vitro drug release is a 
crucial step in paving the way for good permeation. The in 
vitro release of SC from the selected SLN (X6) and NLC (N6) 
formulations was assessed using the dialysis bag method. 
As demonstrated in Figure 3, the release from both SLN 
and NLC dispersions was significantly higher than from 
drug suspension under the same experimental conditions. 
On the other hand, drug release from NLC formulation N6 
was significantly higher than SLN formulation X6. These 
results are consistent with those obtained by Fang et al,16 
who reported higher drug flux from NLCs than SLNs across 
an artificial membrane. They proposed that incorporation 
of liquid lipids into the solid lipid matrix caused the NLCs 
to become more imperfect, with the implication of easier 
drug release. In addition, the lower globular size of NLCs 
(100 nm), compared with SLNs (180 nm), may also partici-
pate in higher drug release.
It is worth noting that the lower particle size of NLCs 
(100 nm) compared with SLNs (180 nm) has been reported 
elsewhere.16 This could indicate better emulsification of the 
solid lipid matrix when oil is incorporated in the solid matrix. 
These results agree with findings from the authors’ previous 
study19 where a nanoemulsion was prepared using M in the 
oil blend and the same surfactant mixture of nanoparticles. 
The nanoemulsion exhibited further decrease in particle size 
(70 nm) compared with oil-loaded SLNs (100 nm) and SLNs 
themselves (180 nm).
The optimization steps resulted in preparation of SC-
loaded nanomedicines with promising in vitro characteristics. 
The ingredients utilized in SLN and NLC formulations are 
recognized for both oral and topical application. A future 
point of interest is the study of oral delivery of SC-loaded 
nanoparticles, considering incorporation of a bioactive 
surfactant-affecting cytochrome enzyme (CR), reported 
advantages of lipid nanoparticles in oral lymphatic target-
ing, and the capability of freeze-drying for preparation of 
nanocarriers as solid oral dosage form.9,28 In the current 
study, the transdermal permeation potential of the elaborated 
nanoparticles via human skin was assessed.
Transdermal permeation study
Excised human skin is properly regarded as the “gold 
standard” for in vitro penetration experiments related to 
human dermal risk assessment. Numerous animal skin 
models from various mammals and reptiles have been 
developed as surrogates for human skin.29,30 Nevertheless, 
animal skin tends to be more permeable than human skin.23 
Consequently, full-thickness human skin was utilized in the 
current study.
In order to investigate the effect of external-phase pH, SC 
permeation levels from two different suspensions (carbon-
ate buffer [pH 10.3] and water) were compared. As revealed 
in Figure 4, both suspensions exhibited low initial drug 
  permeation (in the first 3 hours), which may be attributed to 
the formidable barrier of the stratum corneum. Subsequently, 
higher SC permeation was observed from the alkaline 
  carbonate buffer than from the water suspension. This result 
is consistent with that obtained by Lia and Chang,2 who 
reported pH-dependent permeation of SC via nude mouse 
skin.4 On the other hand, drug permeation rates from both 
Table 5 Peak onset, melting point, and enthalpy data of differential 
scanning calorimetry analysis
Sample Onset  
(°C)
Melting  
point (°C)
Enthalpy  
(J/g)
cP   40.89 ± 0.08   45.59 ± 0.12 151.60 ± 0.98
cP:M Ph MIX  
(0.7:0.3)
  34.46 ± 0.07   44.49 ± 0.09 107.50 ± 0.85
cP:M:cr Ph MIX  
(0.7:0.3:1.3)
  37.99 ± 0.06   44.92 ± 0.14   54.16 ± 0.17
sLNs   35.47 ± 0.33   43.59 ± 0.25   11.06 ± 0.16
NLcs   34.63 ± 0.15   42.47 ± 0.23   13.40 ± 0.12
sc 186.70 ± 0.49 190.75 ± 0.52 264.90 ± 0.63
Note: Data presented as mean ± standard deviation.
Abbreviations: CP, cetyl palmitate; CR, Cremophor® RH 40; M, Maisine™ 35-1; 
NLCs, nanostructured lipid carriers; PH MIX, physical mixture; SC, sildenafil citrate; 
sLNs, solid lipid nanoparticles.
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Figure 3 In vitro release profiles of sildenafil citrate from nanostructured lipid 
carriers (NLCs), and solid lipid nanoparticles (SLNs) compared with drug suspension 
in carbonate buffer (pH 10.3) (citrate buffer, pH 5).
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Figure 4 Transdermal permeation of sildenafil citrate (SC)-loaded nanoparticles 
across human skin versus drug suspensions in water and carbonate buffer (pH 10.3) 
(citrate buffer, pH 5).
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nanocarriers were significantly higher than from both drug 
suspensions, with significantly higher initial SC permeation 
and subsequent sustained release.
In the field of transdermal drug delivery, small 
particle size is implicated as large surface area and film 
formation that consequently creates intimate drug contact 
with the corneocytes. In this way, the nanosize of NLCs 
(100 nm) and SLNs (180 nm) is expected to increase 
the amount of encapsulated drug penetrating into the 
viable skin.12 Furthermore, the occlusive effect of lipid 
nanodispersions increases hydration of the stratum, which 
by reducing corneocyte packing and widening of the inter-
corneocyte gaps can facilitate drug penetration via skin. 
Occlusive effects appear strongly related to particle size; 
therefore, nanoparticles were reported to be significantly more 
occlusive than microparticles.18 An additional mechanism of 
enhancement involves the fact that surfactants can loosen or 
fluidize the lipid bilayers of the stratum corneum and thus 
act as permeation enhancers.16 It is worth noting that both 
SLNs and NLCs exhibited almost the same initial permeation 
profile, whereas higher SC permeation from NLCs than from 
SLNs was observed after 5 hours of application. This could 
be attributed to lower particle size and better drug release 
from the particles as manifested in dialysis experiment.
stability study
As a general consensus, waxes such as CP have been 
reported to exhibit higher physical stability than glycerides, 
owing to highly ordered crystal packing.26,31 In view of the 
current study, both nanoparticle dispersions were stored in 
closed bottles at 4°C in an attempt to investigate physical 
stability of SLNs and NLCs in liquid state. Particle size and 
EE data are shown in Table 6. Visual inspection revealed 
no aggregations or separation for SLNs or NLCs over the 
study period. Results revealed that both SLNs and NLCs 
kept their particle size, indicating good physical stability of 
the particles. In addition, EE values were also unchanged; 
this reflects avoidance of drug expulsion in the formulations 
elaborated for the period of the study. Results are consistent 
with those obtained by Jenning and Gohla,26 who reported 
high physical stability of CP, the wax utilized. In addition, 
avoidance of HPH is proposed to play a part in enhancing 
the stability of nanoparticles.
Conclusion
SC is a first-line treatment drug for erectile dysfunction. 
However, oral delivery of SC is hampered by various 
drawbacks including first-pass metabolism, numerous side 
effects, relatively short duration, and long onset of action. 
Furthermore, drug delivery formulation and transdermal 
application of SC is challenged by its amphoteric nature, low 
oil and water solubility, pH-dependent characteristics, and 
poor membrane permeability. In the current investigation, 
two different types of SC-loaded nanocarriers were optimized 
to improve drug characteristics and transdermal permeation. 
SC-loaded NLCs and SLNs could be elaborated to possess 
excellent EE and particle size. The optimized nanoparticles 
exhibited in vitro drug release superior to that of drug 
  suspension. Elaborated NLCs had smaller particle size and 
higher drug release than SLNs. Both nanocarriers exhibited 
excellent stability for the study period. SLNs and NLCs 
exhibited enhanced transdermal permeation of SC via human 
skin, with higher initial release and controlled permeation 
profile than drug suspension alone. The NLCs elaborated in 
this study did not exhibit the usual significant superiority over 
SLNs in EE and stability. This was attributed to the highly 
ordered crystalline structure of CP, with minimum disruption 
of the structure upon addition of the small percentage of oily 
phase. Nanocarriers developed in this study have successfully 
improved SC transdermal permeation via human skin, with 
promising implications for shorter onset and longer duration 
of drug action. Furthermore, the formulated nanoparticles 
possess promising in vitro characteristics for oral and sub-
lingual delivery, an area for future study.
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